Concordia Healthcare (CHEHF) 27.0700 $CHEHF
Concordia Healthcare Corp. to Host First Quarter 2014 Results Conference Call
CNW Group - Mon May 05, 1:00PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its first quarter 2014 financial results on Thursday, May 15, 2014, before market open. The Company will subsequently hold a conference call on Thursday, May 15, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
Concordia Healthcare Announces Fiscal 2013 Results (May 2013 - December 2013)
PR Newswire - Mon Mar 31, 6:00AM CDT
Company's board approves an annualized US$0.30 dividend -
FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber
PR Newswire - Wed Mar 26, 7:00AM CDT
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle", a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber.
Concordia Healthcare Corp. to Host Fiscal 2013 Year-End Results Conference Call
CNW Group - Mon Mar 24, 3:00PM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
Concordia Healthcare Announces Agreement to Acquire Donnatal®
PR Newswire - Thu Mar 20, 6:30AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS" and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals".
IIROC Trade Resumption - Concordia Healthcare Corp.
Newsfile Corp - Wed Feb 19, 7:22AM CST
Trading resumes in:
IIROC Trade Halt - Concordia Healthcare Corp.
Newsfile Corp - Tue Feb 18, 2:57PM CST
The following issues have been halted by IIROC:
Concordia Healthcare Corp. begins trading on OTCQX® in U.S.
CNW Group - Thu Jan 30, 8:02AM CST
Announcement follows recent listing on Toronto Stock Exchange
Concordia Healthcare Corp. Begins Trading on OTCQX®
PR Newswire - Thu Jan 30, 7:31AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Concordia Healthcare Corp. ("Concordia" (OTCQX: CHEHF; TSX: CXR), a diverse healthcare company, has been approved to trade on OTCQX®, the best marketplace with qualified companies.
Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
PR Newswire - Mon Jan 13, 7:00AM CST
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle", a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with the U.S. Food and Drug Administration (the "FDA" under a special protocol assessment (the "SPA" to enroll patients with an advanced form of bile duct cancer in a pivotal Phase 3 clinical trial. There is currently no approved therapy for this cancer type. The SPA is a written agreement between Pinnacle and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application submission. The clinical trial will study the efficacy and safety of photodynamic therapy ("PDT" with PHOTOFRIN® (porfimer sodium) for injection as treatment for unresectable advanced perihilar cholangiocarcinoma ("CCA" Bismuth type III/IV.
Concordia Healthcare Corp. announces Exclusive Distribution Agreement for Ulesfia® with Lachlan Pharma Holdings
PR Newswire - Mon Jan 06, 7:23AM CST
TSX: CXR
Concordia Healthcare Corp. to Host First Quarter 2014 Results Conference Call
CNW Group - Mon May 05, 1:00PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its first quarter 2014 financial results on Thursday, May 15, 2014, before market open. The Company will subsequently hold a conference call on Thursday, May 15, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update. Concordia Healthcare Announces Fiscal 2013 Results (May 2013 - December 2013)
PR Newswire - Mon Mar 31, 6:00AM CDT
Company's board approves an annualized US$0.30 dividend -
FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber
PR Newswire - Wed Mar 26, 7:00AM CDT
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"
, a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber. Concordia Healthcare Corp. to Host Fiscal 2013 Year-End Results Conference Call
CNW Group - Mon Mar 24, 3:00PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update. Concordia Healthcare Announces Agreement to Acquire Donnatal®
PR Newswire - Thu Mar 20, 6:30AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS"
and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals". IIROC Trade Resumption - Concordia Healthcare Corp.
Newsfile Corp - Wed Feb 19, 7:22AM CST
Trading resumes in:
IIROC Trade Halt - Concordia Healthcare Corp.
Newsfile Corp - Tue Feb 18, 2:57PM CST
The following issues have been halted by IIROC:
Concordia Healthcare Corp. begins trading on OTCQX® in U.S.
CNW Group - Thu Jan 30, 8:02AM CST
Announcement follows recent listing on Toronto Stock Exchange
Concordia Healthcare Corp. Begins Trading on OTCQX®
PR Newswire - Thu Jan 30, 7:31AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Concordia Healthcare Corp. ("Concordia"
(OTCQX: CHEHF; TSX: CXR), a diverse healthcare company, has been approved to trade on OTCQX®, the best marketplace with qualified companies. Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
PR Newswire - Mon Jan 13, 7:00AM CST
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"
, a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with the U.S. Food and Drug Administration (the "FDA" under a special protocol assessment (the "SPA" to enroll patients with an advanced form of bile duct cancer in a pivotal Phase 3 clinical trial. There is currently no approved therapy for this cancer type. The SPA is a written agreement between Pinnacle and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application submission. The clinical trial will study the efficacy and safety of photodynamic therapy ("PDT" with PHOTOFRIN® (porfimer sodium) for injection as treatment for unresectable advanced perihilar cholangiocarcinoma ("CCA" Bismuth type III/IV. Concordia Healthcare Corp. announces Exclusive Distribution Agreement for Ulesfia® with Lachlan Pharma Holdings
PR Newswire - Mon Jan 06, 7:23AM CST
TSX: CXR
